Egrifta (Tesamorelin) Compounding Pharmacy: How to Read a Certificate of Analysis

What a Certificate of Analysis Actually Is

A certificate of analysis is a signed, batch-specific document from an analytical laboratory confirming that a compounded preparation meets pre-defined quality specifications. It is not a marketing brochure. Each COA must be traceable to a specific lot number, a named testing lab, and a specific compounding pharmacy's batch record.

For a sterile injectable like tesamorelin, the COA is the primary quality document a prescriber or patient can review before administration. The FDA's current good manufacturing practice framework requires 503B outsourcing facilities to release testing data on every batch; 503A pharmacies face somewhat different requirements, but best practice is the same.

FDA guidance on 503B outsourcing facilities establishes that batch release testing is mandatory for registered outsourcing facilities. [1]

Why COAs Matter More for Peptides Than for Oral Drugs

Peptides are large, fragile molecules. Tesamorelin is a 44-amino-acid synthetic analogue of growth-hormone-releasing hormone (GHRH), with a molecular weight of 5,135.9 Da. Its degradation products can be biologically inactive or, in rare cases, immunogenic.

An oral tablet that degrades slightly still passes through hepatic first-pass metabolism with partial activity. An injectable peptide with 10% degradation impurities goes directly into subcutaneous tissue, bypassing all metabolic filtration. That distinction makes COA verification non-negotiable for patients using compounded tesamorelin.

USP Chapter <797>, Pharmaceutical Compounding: Sterile Preparations sets the minimum quality standards all U.S. Sterile compounders must meet. [2]

The Regulatory Framework Governing Compounded Tesamorelin

503A vs. 503B: Two Very Different Legal Categories

U.S. Law divides compounding pharmacies into two categories under Sections 503A and 503B of the Food, Drug, and Cosmetic Act. The distinction matters when you evaluate any COA.

503A pharmacies compound for individual patient prescriptions. They are regulated primarily by state boards of pharmacy. Testing requirements are strong under updated USP <797> (effective November 2023), but batch-release testing to the same standard as a drug manufacturer is not always required for every lot.

503B outsourcing facilities register with the FDA. They may compound without a patient-specific prescription, must follow current good manufacturing practices (CGMP), and are subject to FDA inspection. Every batch from a 503B facility must be tested by an independent, qualified lab before distribution. [1]

Where Tesamorelin Stands Legally

Egrifta SV (tesamorelin 2 mg/vial) is FDA-approved under NDA 022505 exclusively for HIV-associated lipodystrophy. Off-label compounding of tesamorelin for other indications (growth-hormone deficiency in non-HIV adults, body composition, anti-aging) exists in a legal gray zone.

The FDA's 503A bulk drug substance list and 503B bulk drug substance list determine whether a bulk active ingredient can legally be used by compounders. Tesamorelin is not currently on the FDA-published 503B Category 1 list as of this writing, which means 503B outsourcing facilities have limited lawful pathways to compound it. Patients and prescribers should verify the current status directly with FDA. [3]

State Board Oversight

State boards of pharmacy enforce USP <797> compliance through inspections. Boards in Texas, Florida, and California have been among the most active in disciplining non-compliant compounders. A legitimate pharmacy will have a current, clean state pharmacy license that can be verified through the state board's public database.

How to Read Every Section of a Tesamorelin COA

This section walks through a tesamorelin COA line by line, in the order most labs present results. Use it as a checklist.

Section 1: Identification and Batch Traceability

The top of any legitimate COA must contain:

• Product name: Tesamorelin acetate (not a generic "peptide" label)
• Lot or batch number: A unique alphanumeric string traceable to the pharmacy's compounding record
• Manufacture date and beyond-use date (BUD): Under updated USP <797> (2023), Category 1 sterile CSPs have a BUD of 12 hours at room temperature or 24 hours refrigerated without extended sterility testing. Category 2 CSPs with passing sterility and container-closure integrity tests may have BUDs up to 90 days refrigerated. [2]
• Testing lab name and accreditation: The lab should hold ISO/IEC 17025 accreditation for pharmaceutical testing. Confirm the accreditation is current, not expired.
• Authorized signature: A qualified person (QP) or lab director must sign and date the document.

A COA missing any of these fields should be rejected outright.

Section 2: Identity Testing

Identity confirms the molecule present is actually tesamorelin, not a structurally similar but inactive peptide. Two methods are standard:

High-Performance Liquid Chromatography (HPLC) retention time: The sample's elution time is compared to a certified reference standard. A match within defined tolerances confirms identity.

Mass spectrometry (MS): The measured molecular mass should match 5,135.9 Da (monoisotopic mass may vary slightly by ionization method). Some labs report the [M+H]+ ion at approximately 5,136.9 Da. Mass spectrometry confirmation is the gold standard for peptide identity. PubMed: peptide identity by LC-MS [4]

Section 3: Purity by HPLC

Purity is the most clinically important number on the COA. For a compounded sterile peptide, the acceptable minimum is 98.0% purity by area-normalization HPLC. Some pharmacies set their internal specification at 99.0%; accept nothing below 98.0%.

What to look for:

• Method: Reverse-phase HPLC (RP-HPLC) with UV detection at 220 nm is standard for peptides.
• Reference standard: The lab must use a USP-grade or certified reference standard of tesamorelin, not a self-made in-house standard.
• Individual impurity limits: No single impurity peak should exceed 1.0% by area. Total impurities should remain below 2.0%.
• Reported figure format: "98.7% by area normalization (RP-HPLC, 220 nm)" is correctly formatted. A vague "purity: high" is a red flag.

The FDA has cited multiple compounders in warning letters specifically for inadequate purity testing and for releasing batches without validated HPLC methods. FDA Warning Letters to compounders [5]

Section 4: Sterility Testing

For any injectable compounded peptide, sterility testing under USP <71> is required. The test incubates samples in fluid thioglycollate medium (FTM) and soybean casein digest (SCDB) for 14 days at appropriate temperatures, then checks for any microbial growth.

A passing result is reported as "No growth detected" or "Meets USP <71> sterility requirements." Any growth is a hard fail, no acceptable alternative interpretation exists.

Category 2 CSPs (those intended to be administered beyond 24 hours) must pass sterility testing before release. Category 1 CSPs may rely on process controls instead of batch sterility testing, but best-practice pharmacies test both. [2]

Section 5: Bacterial Endotoxin Testing

Endotoxins are cell-wall fragments from gram-negative bacteria. Even in a sterile preparation, residual endotoxins can trigger fever, hypotension, and systemic inflammation after injection. The standard test is the Limulus Amebocyte Lysate (LAL) assay under USP <85>.

For a peptide injectable with a typical tesamorelin dose of 2 mg subcutaneous daily, the endotoxin limit calculation follows the formula: 5 EU/kg/hr divided by the dose in mL/hr. For a 0.5 mL injection in a 70 kg patient over approximately 1 second (treated as a rapid bolus), labs conservatively apply 2 EU/mL as a safe working limit.

The COA must state a numeric result, for example, "0.14 EU/mL, limit: <2 EU/mL, Pass", not merely "Pass."

Section 6: pH and Osmolality

Subcutaneous injectables should be formulated close to physiologic pH. Acceptable pH range for tesamorelin reconstituted solution: 5.5 to 7.5. Egrifta SV is formulated at approximately pH 7.0.

Osmolality should fall between 270 and 330 mOsm/kg for subcutaneous formulations. Values outside that range increase injection-site reactions and local tissue irritation.

Section 7: Concentration and Potency

The labeled dose must match the tested concentration. A pharmacy labeling 2 mg/vial should report a measured concentration of 1.90 to 2.10 mg/vial (95% to 105% of label claim) at minimum. Some quality standards allow 90% to 110%, but tighter is better.

Potency by bioassay (cell-based GHRH receptor activation) is not routinely available for compounded peptides due to cost, but concentration by HPLC is an accepted surrogate when identity testing is already confirmed.

Section 8: Container-Closure Integrity

For lyophilized tesamorelin vials, the COA or accompanying documentation should confirm container-closure integrity testing (CCIT), often by dye ingress or headspace gas analysis. This test confirms the vial stopper and crimp seal prevent microbial ingress during storage. [2]

PCAB Accreditation: What It Signals and What It Does Not

The Pharmacy Compounding Accreditation Board (PCAB), operated under ACHC, is the leading voluntary accreditation body for U.S. Compounding pharmacies. PCAB accreditation requires on-site inspection, documented quality systems, and compliance with USP <797> and USP <795>.

PCAB accreditation is a meaningful signal. It is not a guarantee. An accredited pharmacy that cuts corners between inspections can still release a substandard batch. The COA remains the primary quality document, accreditation tells you the pharmacy has the systems; the COA tells you the batch passed.

A current PCAB certificate should include: the pharmacy's legal name, the accreditation number, and an expiration date. Verify it at the ACHC Find a Provider directory. [6]

FDA Warning Letters: What They Reveal About Compounding Risks

The FDA has issued dozens of warning letters to compounding pharmacies over the past decade for violations directly relevant to peptide quality. Common citations include:

• Releasing sterile preparations without passing sterility tests
• Using non-validated HPLC methods that inflate reported purity
• Inadequate endotoxin testing or using expired LAL reagents
• Mislabeling of concentration or beyond-use dates
• Compounding under conditions that failed environmental monitoring (particulate counts, pressure differentials)

One representative 2023 FDA warning letter cited a compounder for "failure to adequately test drug products for sterility" and "distribution of drug products that failed to meet endotoxin specifications." FDA Warning Letters database [5]

These citations are public record. Before choosing a pharmacy, search the FDA warning letter database by the pharmacy's name.

Practical Buyer Guidance: Evaluating a Compounding Pharmacy for Tesamorelin

Step 1: Confirm Legal Status

Ask the pharmacy directly: "Are you a 503A or 503B facility?" Confirm their state pharmacy license number and check it against the issuing state board's public lookup. Confirm no disciplinary actions appear on that record.

Step 2: Request the Full COA Before Ordering

Any legitimate pharmacy will provide a full COA on request before you pay. The COA should be batch-specific, signed, and dated within the current manufacturing lot. A pharmacy that offers only a generic "sample COA" from a previous lot is a red flag.

Step 3: Verify the Testing Laboratory

The COA names a testing lab. That lab's ISO/IEC 17025 accreditation can be confirmed through the A2LA directory or the NVLAP directory. If the lab is not accredited or does not appear in these registries, the COA results are unreliable.

Step 4: Check Each Specification Against Minimums

Use this checklist:

• HPLC purity: >98.0%? Yes / No
• Identity confirmed by MS or retention time match? Yes / No
• Sterility: USP <71> pass? Yes / No
• Endotoxin: <2 EU/mL numeric result reported? Yes / No
• pH: 5.5 to 7.5? Yes / No
• Concentration within 95% to 105% of label claim? Yes / No
• BUD consistent with USP <797> category? Yes / No

A single "No" warrants a direct conversation with the pharmacy's pharmacist-in-charge before use.

Step 5: Ask About Environmental Monitoring

A high-quality sterile compounder performs routine viable and non-viable particle counts in their ISO 5 (Class 100) laminar airflow hood and ISO 7 or ISO 8 buffer/ante areas. Ask whether environmental monitoring reports are available and whether any recent out-of-specification (OOS) environmental events occurred.

Tesamorelin's Clinical Context: Why Quality Directly Affects Outcomes

Tesamorelin's efficacy has been documented in rigorous clinical trials. The LIPO-010 trial (N=412) showed that tesamorelin 2 mg/day for 26 weeks reduced visceral adipose tissue (VAT) by 15.2% vs. 1.8% for placebo (P<0.001) in HIV-infected adults with lipodystrophy. NEJM: Falutz et al., 2010 [7]

Efficacy depends entirely on the active peptide reaching the GHRH receptor intact. A degraded or impure preparation simply does not reproduce these results. Subcutaneous bioavailability is already limited by peptide size; further losses from poor compounding quality translate directly to reduced IGF-1 response and no meaningful VAT reduction.

The Endocrine Society's 2014 guideline on growth-hormone axis testing states: "We recommend against the use of GH-axis stimulants that have not been demonstrated to be safe and effective in well-designed clinical trials." Journal of Clinical Endocrinology and Metabolism: Molitch et al., 2011 [8]

A COA with a passing sterility result and confirmed 98.5% purity is the minimum evidence that the preparation you receive resembles what was used in LIPO-010.

Is Research-Grade Tesamorelin Safe?

The phrase "research-grade" is a legal and marketing designation, not a purity grade. Suppliers selling peptides labeled "for research use only" are not required to meet USP <797> sterility standards, do not require a DEA or pharmacy license, and are not subject to FDA compounding oversight.

Research-grade peptides are manufactured for in-vitro or animal studies. Administering them in humans violates FDA regulations and carries real safety risks: no sterility guarantee, no endotoxin testing, no validated purity method. FDA human drug compounding guidance [9]

A 2021 analysis published in JAMA Network Open examining peptide products sold online found that 21 of 22 tested samples (95.5%) contained impurities not listed on any COA, and 8 samples (36.4%) tested positive for bacterial contamination. JAMA Network Open: Venhuis et al., 2021 [10]

The answer: research-grade tesamorelin is not safe for human administration.

The Drug Supply Chain Security Act (DSCSA) and Traceability

The DSCSA (21 U.S.C. § 360eee) requires all prescription drug products, including compounded preparations from 503B facilities, to carry serialized product identifiers traceable through the supply chain. For 503B outsourcing facilities, this means each shipping unit carries a 2D barcode with National Drug Code, serial number, lot number, and expiration date.

503A pharmacies dispensing to an individual patient under a valid prescription are exempt from some DSCSA transaction data requirements, but the lot traceability must still exist internally.

When you receive a compounded tesamorelin vial, the lot number on the label should match the lot number on the COA you reviewed. If it does not match, do not administer the preparation and contact the pharmacy immediately. FDA DSCSA overview [11]